Curriculum in cardiology: Integrated diagnosis and management of diastolic heart failure

被引:50
作者
Chinnaiyan, Kavitha M.
Alexander, Daniel
Maddens, Michael
McCullough, Peter A.
机构
[1] William Beaumont Hosp, Div Nutr & Prevent Med, Royal Oak, MI 48073 USA
[2] William Beaumont Hosp, Div Cardiol, Royal Oak, MI 48073 USA
[3] William Beaumont Hosp, Div Geriatr Med, Royal Oak, MI 48073 USA
关键词
D O I
10.1016/j.ahj.2006.10.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Among the general heart failure (HF) population, over half have diastolic HF (DHF). The proportion of DHF increases with age, from 46% in patients younger than 45 years to 59% in patients older than 85 years. The diagnosis of DHF is made by the combination of signs and symptoms of HF with preserved systolic function (left ventricular ejection fraction > 50%), and evidence of diastolic dysfunction obtained by echocardiographic Doppler examination, invasive hemodynamic evaluation, or an elevation of serum B-type notriuretic peptide. The most common risk factors for the development of diastolic dysfunction and DHF include long-standing hypertension, older age, female sex, obesity, diabetes, chronic kidney disease, and coronary artery disease. Acute decompensation occurs in the setting of pressure overload, volume overload, or superimposed cardiac ischemia. The cornerstones of in-hospital management include blood pressure and volume control, heart rate control, and correction of precipitating factors. Priorities in the outpatient clinic include optimal blood pressure control, maintenance of euvolemia with minimal or no diuretics, and, potentially, use of disease-modifying drugs including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, aldosterone receptor blockers, beta-blockers, and digoxin. Long-term regression of left ventricular hypertrophy, improvement in diastolic filling parameters, and sustained reductions in B-type natriuretic peptide may be future treatment targets for this condition.
引用
收藏
页码:189 / 200
页数:12
相关论文
共 49 条
  • [1] ABOUFAKHER R, 2005, ANN SCI SESS SOC GER
  • [2] ALPERT MA, 1995, INT J OBESITY, V19, P550
  • [3] Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy
    Araujo, AQ
    Arteaga, E
    Ianni, BM
    Buck, PC
    Rabello, R
    Mady, C
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (11) : 1563 - 1567
  • [4] Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure
    Baicu, CF
    Zile, MR
    Aurigemma, GP
    Gaasch, WH
    [J]. CIRCULATION, 2005, 111 (18) : 2306 - 2312
  • [5] BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.ph.54.030192.001303
  • [6] Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease
    Brilla, CG
    Funck, RC
    Rupp, H
    [J]. CIRCULATION, 2000, 102 (12) : 1388 - 1393
  • [7] BRILLA CG, 1993, AM J CARDIOL, V71, P12
  • [8] Doppler tissue analysis of mitral annular velocities: Evidence for systolic abnormalities in patients with diastolic heart failure
    Bruch, C
    Gradaus, R
    Gunia, S
    Breithardt, G
    Wichter, T
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2003, 16 (10) : 1031 - 1036
  • [9] DUAL CONTROL OF RELAXATION - ITS ROLE IN THE VENTRICULAR-FUNCTION IN THE MAMMALIAN HEART
    BRUTSAERT, DL
    HOUSMANS, PR
    GOETHALS, MA
    [J]. CIRCULATION RESEARCH, 1980, 47 (05) : 637 - 652
  • [10] Chinnaiyan Kavitha M, 2005, J Clin Hypertens (Greenwich), V7, P740, DOI 10.1111/j.1524-6175.2005.04889.x